In an age where mobile apps, big data and sophisticated technology seem to dominate every conversation about health care innovation, Jamie Harris’s quality improvement project might not seem so revolutionary. But Harris, a nurse in the cardiac electrophysiology program at Boston Children’s Hospital, saw an opportunity to take an existing patient safety initiative and use it in a new way. …
Some great inventions were on view this week at the second annual Boston Children’s Hospital Innovators Showcase. Hosted by the hospital’s Innovation Acceleration Program and Technology & Innovation Development Office, the event featured everything from virtual reality goggles with gesture control to biomedical technologies. Below are a few new projects that caught Vector’s eye (expect to hear more about them in the coming months), a kid-friendly interview about the SimLab and list of inventions kids themselves would like to see. (Photos by Katherine Cohen except as noted) …
You’d think drugs for a condition affecting millions of children would be tested in many, many children to catch any rare side effects.
You’d think all this would happen before the Food and Drug Administration, an agency known for its strict criteria, approved them for marketing.
In it, the pair reports that the FDA approved 20 attention deficit hyperactivity disorder (ADHD) drugs over the last 60 years without what would be considered sufficient long-term safety and rare adverse event data.
Their findings, they say, point to larger issues in how the FDA’s approval process addresses the long-term safety of drugs intended for chronic use in children. …
As we reported on Vector last year, once a new drug is on the market, regulators rely on a mix of surveillance, reporting and data mining to detect adverse drug events (aka side effects).
While those methods can work pretty well, a team of scientists from Microsoft, Stanford and Columbia wanted a better way to find rare or unforeseen interactions between drugs and recently tried a new tactic: looking at what people type into Internet search engines like Google, Microsoft and Yahoo. They hit pay dirt, unearthing evidence that the combination of two drugs—the antidepressant paroxetine and a cholesterol-lowering drug called pravastatin—leads to high blood sugar.
“Given how often patients turn to the Internet for information about the drugs they are taking, it’s not unexpected that we will identify new side effects sooner,” says John Brownstein, PhD, leader of the Computational Epidemiology Group in the Children’s Hospital Informatics Program (CHIP), and whose MedWatcher mobile app takes a crowdsourcing approach to drug side-effect reporting.
The work is another demonstration of the power that search tools, social media and other alternative data sources can bring to public health surveillance. In 2011, Brownstein and colleagues demonstrated that Google searches could reveal a lot about peoples’ health behaviors. “There is tremendous promise in a wide range of tools, from online search to patient forums. We are just now at the start of a new era for drug safety surveillance,” Brownstein notes.
At the same time, the work also emphasizes the need for the public, Internet companies, privacy advocates, health care thought leaders and other stakeholders to agree on ground rules for using data like these for health surveillance. We are, after all, in an era in which everything we do is online.
“As we uncover new uses for these data, there is an important conversation to be had,” says Ben Reis, PhD, leader of CHIP’s Predictive Medicine Group. Reis is working on ways of mathematically predicting possible adverse events. “We have to ensure that the public understands both the potential value of the data for helping society at large, as well as the safeguards that are in place to protect individual privacy.”
A major challenge in drug development is figuring out what might go wrong. During the development process, a new drug might be given to a few thousand people, maybe fewer if it’s for a rare or orphan disease – just enough to tell whether it does what the researchers think it will and to establish its short-term safety.
Once a drug is approved and available to the public, and out of the controlled laboratory or clinical trial environment, regulators rely on a mix of surveillance, reporting (by doctors and patients) and data mining to catch problems.
But these methods can fall short when it comes to rare side effects, drug-drug interactions or adverse events that arise only after patients have been on a drug for a long time. It can be years before doctors and regulators gather enough data and address safety problems with label warnings, revised prescribing guidelines or, in extreme cases, removal from the market.
So while detection works to a point, wouldn’t it be better if we could predict adverse drug events before a drug even hits the market? …
The question comes up when a pregnant woman has a serious medical condition: should she or shouldn’t she be treated? Are the indicated drugs safe for the baby?
Drugs are assigned pregnancy risk classes. Thalidomide, whose reputation for causing fetal malformations was chillingly established in the 1960s, is solidly in Class X (the most risky), as are the cholesterol-lowering drug lovastatin and the anti-coagulant warfarin. At the other extreme are Class A drugs that are widely recognized as safe in pregnancy.
But between these extremes is a huge group of drugs for which little is known. …